Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy.

ABSTRACT:

Objective

To select optimal therapies based on the detection of actionable genomic alterations in tumor samples is a major challenge in precision medicine.

Methods

We describe an effective process (opened December 1, 2017) that combines comprehensive genomic and transcriptomic tumor profiling, custom algorithms and visualization software for data integration, and preclinical 3-dimensiona ex vivo models for drug screening to assess response to therapeutic agents targeting specific genomic alterations. The process was applied to a patient with widely metastatic, weakly hormone receptor positive, HER2 nonamplified, infiltrating lobular breast cancer refractory to standard therapy.

Results

Clinical testing of liver metastasis identified BRIP1, NF1, CDH1, RB1, and TP53 mut

SUBMITTER: Vasmatzis G 

PROVIDER: S-EPMC7251931 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature